logo
Share SHARE
FONT-SIZE Plus   Neg

Merck Announces New Phase III Data For Suvorexant - Quick Facts

Merck & Co. Inc. (MRK) announced the new Phase III Data for suvorexant, the investigational medicine the compoany is developing for the treatment of insomnia.

The 12-month study was designed to assess the safety of suvorexant, while also evaluating its longer term efficacy. The company said it presented new results from a two-month discontinuation phase that followed the 12-month study at the 21st Congress of the European Sleep Research Society or ESRS.

The company said that the results from the two-month discontinuation phase showed that, after daily use of a consistent dose of suvorexant for one year, patients who stopped taking the medicine experienced a return of their sleeping difficulties to levels similar to those reported by patients who received placebo over the course of the trial.

The company noted that Patients who continued to receive suvorexant for the additional two months experienced mean improvements in their ability to fall asleep and stay asleep that were consistent with those seen over the first 12 months compared to placebo. Adverse experiences reported in the two-month discontinuation phase were generally consistent with those reported during the 12-month study.

The company stated that it plans to file a New Drug Application (NDA) for suvorexant with the U.S. Food and Drug Administration or FDA in 2012. If approved, suvorexant would be the first in a new class of medicines, called orexin receptor antagonists, for use in patients with difficulty falling or staying asleep. The company said it anticipates that suvorexant will be evaluated by the Controlled Substance Staff of the FDA.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Sanofi (SNYNF, SNY) reported that its fourth-quarter net income attributable to equity holders decreased to 334 million euros from 1.34 billion euros, last year. Earnings per share was 0.26 euros compared to 1.02 euros. Earnings per share excluding the held for exchange Animal Health Business was 0.41... Tour operator TUI Group reported narrower EBITA loss in its first quarter with increased turnover, driven by strong performances in Northern Region and Cruises. Further, the company said its current trading for Winter 2015/2016 and Summer 2016 remains in line with its expectations. Looking ahead, TUI reiterated its outlook to deliver underlying EBITA growth of at least 10 percent in fiscal 2016. Yelp Inc. (YELP) on Monday posted a loss for the fourth quarter compared to a profit last year, as higher revenues were offset by increase in operating costs. Yelp said its Chief Financial Officer Rob Krolik was leaving the company. Yelp reported fourth-quarter loss of $22.2 million or $0.29 per share,...
comments powered by Disqus
RELATED NEWS
Trade MRK now with 
Follow RTT